Evidence map›Paper›PMID 25437426›Full record

ArticleThe Journal of investigative dermatology2015

Premature skin aging features rescued by inhibition of NADPH oxidase activity in XPC-deficient mice.

Mohsen Hosseini, Walid Mahfouf, Martin Serrano-Sanchez, Houssam Raad, Ghida Harfouche, Marc Bonneu, Stephane Claverol, Frederic Mazurier, Rodrigue Rossignol, Alain Taieb and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in Cholangiocarcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention.International journal of molecular sciences · 2019
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Therapeutic potential of NADPH oxidase 1/4 inhibitors.British journal of pharmacology · 2017
    Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mohsen HosseiniInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Walid MahfoufInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Martin Serrano-SanchezInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Houssam RaadInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Ghida HarfoucheInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Marc BonneuCentre Génomique Fonctionnelle de Bordeaux, Université de Bordeaux, Bordeaux, France.
Stephane ClaverolCentre Génomique Fonctionnelle de Bordeaux, Université de Bordeaux, Bordeaux, France.
Frederic MazurierInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, France.
Rodrigue RossignolInserm U1035, Bordeaux, France; Université de Bordeaux, Maladies Rares: Génétique et Métabolisme (MRGM), Bordeaux, France.
Alain TaiebInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, France; Département de Dermatologie and Dermatologie Pédiatrique, CHU de Bordeaux, France.
Hamid Reza RezvaniInserm U1035, Bordeaux, France; Université de Bordeaux, Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, France. Electronic address: hamid-reza.rezvani@u-bordeaux.fr.
Université de Bordeaux · FRBordeaux Population Health · FRInserm · FRInstitut de Génomique Fonctionnelle · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xeroderma pigmentosum type C (XP-C) is characterized mostly by a predisposition to skin cancers and accelerated photoaging, but little is known about premature skin aging in this disease. By comparing young and old mice, we found that the level of progerin and p16(INK4a) expression, β-galactosidase activity, and reactive oxygen species, which increase with age, were higher in young Xpc(-/-) mice than in young Xpc(+/+) ones. The expression level of mitochondrial complexes and mitochondrial functions in the skin of young Xpc(-/-) was as low as in control aged Xpc(+/+)animals. Furthermore, the metabolic profile in young Xpc(-/-) mice resembled that found in aged Xpc(+/+) mice. Furthermore, premature skin aging features in young Xpc(-/-) mice were mostly rescued by inhibition of nicotinamide adenine dinucleotide phosphate oxidase 1 (NOX1) activity by using a NOX1 peptide inhibitor, suggesting that the continuous oxidative stress due to overactivation of NOX1 has a causative role in the underlying pathophysiology.

Indexed as

Skin AgingAdaptor Proteins, Signal TransducingAnimalsbeta-GalactosidaseCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsHumansKeratinocytesLamin Type ALightMiceMice, KnockoutMitochondriaNADH, NADPH OxidoreductasesNADPH Oxidase 1Nuclear ProteinsAdaptor Proteins, Signal Transducingbeta-GalactosidaseCdkn2a protein, mouseCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsLamin Type ANADH, NADPH OxidoreductasesNADPH Oxidase 1NOX1 protein, mouseNoxa1 protein, mouseNoxo1 protein, mouseNuclear Proteinsprelamin AProtein PrecursorsProteinsReactive Oxygen SpeciesXpc protein, mouse

Identifiers

PMID25437426
OpenAlexW2065523440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.